WHO ICTRP trial
Feasibility study of ramucirumab plus irinotecan in patients with advanced…
JPRN-UMIN000019075 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000019075 |
|---|---|
| Public title | Feasibility study of ramucirumab plus irinotecan in patients with advanced gastric cancer |
| Scientific title | Feasibility study of ramucirumab plus irinotecan in patients with advanced gastric cancer - Feasibility study of ramucirumab plus irinotecan in patients with advanced gastric cancer |
| Primary sponsor | Osaka University |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not selected |
| Countries | Japan |
| Conditions | chemo-refractory gastric cancer |
| Interventions | Ramucirumab: 8 mg/kg, day1, biweekly Irinotecan: 150 mg/m2, day1, biweekly |
| Registration date | Sep 20, 2015 |
| Target size | 6 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: